BackNeuBase Therapeutics Overview

NeuBase Therapeutics Receivables

Track NeuBase Therapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-127715.00 vs prior year quarter

Peer average

Loading

NeuBase Therapeutics Receivables History

Loading

NeuBase Therapeutics vs. peers: Receivables Comparison

Loading

NeuBase Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NeuBase Therapeutics (NBSE) FAQ

NeuBase Therapeutics (NBSE) currently reports a receivables of $0 as of September 2023. That compares with $130K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore NeuBase Therapeutics's receivables history and peer comparisons.

NeuBase Therapeutics's receivables decreased from $130K to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NeuBase Therapeutics reported $0 in receivables as of September 2023. That compares with $130K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NeuBase Therapeutics, and consider following NBSE for alerts when major investors trade the stock.

NeuBase Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBSE with unrelated industries.